-The Business Standard One correction - and more to come? Several developments in the Supreme Court over illegal mining of iron ore in Karnataka indicate that only the first chapter of a long-running story has been brought to a satisfactory end. The whole story offers a valuable insight into practices of governance and ways of doing business in India. The first chapter began over half a decade ago, with a report by...

-The Economist West Bengal’s populist chief minister is doing badly. Yet she typifies shifts in power in India BUYER’S remorse is common enough in the dusty markets of Kolkata, a delightful if crumbling great city, once known as Calcutta and still capital of the state of West Bengal. Those who buy cheap plastic goods or plaster-of-Paris busts of Rabindranath Tagore, Bengal’s cultural hero, may come to regret their haste. Likewise, many who...

Anand Patwardhan’s paean to Dalits, that took 14 years to compose, probes even as it praises, says Saroj Giri THERE IS an entrenched tendency to represent Dalits fighting for rights and reservations as just (another) competitive bloc vying for self-interest and power. It leads to a pernicious inversion: ‘Dalit rights’ dividing the nation along caste lines. Victim as perpetrator! Anand Patwardhan’s film Jai Bhim Comrade takes us beyond the grid of...

India's efforts to produce and supply life-saving drugs at affordable prices face challenges from multinational companies trying to “evergreen” their patents. THE average life expectancy across the globe has increased from around 30 years a century ago to over 65 years today. This has been made possible in large part by modern medicine. Never before in history have humans had access to such an array of medicines and devices to...

Industry reacts with caution to the grant of a compulsory licence to Natco, but cancer patients welcome it and hope for many more. THE first compulsory licence (CL) issued by the Indian patent office, to the local drug manufacturer Natco Pharma Ltd to sell the generic version of Bayer AG's anti-cancer drug Nexavar, has LED to varied reactions. The landmark decision has also raised concerns about the outcome of cases...